First-line and second-line antiretroviral therapy

The Lancet ◽  
2004 ◽  
Vol 364 (9431) ◽  
pp. 329 ◽  
Author(s):  
Alexandra Calmy ◽  
Fernando Pascual ◽  
Nathan Ford
2017 ◽  
Vol 73 (1) ◽  
pp. 5-11 ◽  
Author(s):  
Seema Patrikar ◽  
Subramanian Shankar ◽  
Atul Kotwal ◽  
D.R. Basannar ◽  
Vijay Bhatti ◽  
...  

2013 ◽  
Vol 32 (6) ◽  
pp. 644-647 ◽  
Author(s):  
Catherine Orrell ◽  
Julie Levison ◽  
Andrea Ciaranello ◽  
Linda-Gail Bekker ◽  
Daniel R. Kuritzkes ◽  
...  

2021 ◽  
Vol 8 (12) ◽  
Author(s):  
Samuel Pierre ◽  
Iryna Bocharova ◽  
Catherine Nguyen ◽  
Fabienne Homeus ◽  
Gaetane Julmiste ◽  
...  

Abstract We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.


AIDS ◽  
2015 ◽  
Vol 29 (12) ◽  
pp. 1527-1536 ◽  
Author(s):  
Sophie Desmonde ◽  
François T. Eboua ◽  
Karen Malateste ◽  
Fatoumata Dicko ◽  
Didier K. Ekouévi ◽  
...  

2016 ◽  
Vol 71 (5) ◽  
pp. 506-513 ◽  
Author(s):  
Andrew Kambugu ◽  
Jennifer Thompson ◽  
James Hakim ◽  
Dinah Tumukunde ◽  
Joep J. van Oosterhout ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document